Infectious Disease Week and Kidney Week on tap.. virtually, of course

Lynne Peterson is the Senior Writer for Trends-in-Medicine.

Here is the medical news to watch for October 19-25, 2020.

Covid-19: FDA’s Vaccines and Related Biological Products Advisory Committee will meet virtually on October 22 for a general discussion of Covid-19 vaccines. This is not a review of any specific vaccine.

Gastroenterology: American College of Gastroenterology (ACG) will take place virtually October 23-28. Topics will range from refractory heartburn to fecal incontinence, irritable bowel syndrome, celiac disease, hepatitis, cutting edge technology, and more.

Infectious diseases: Infectious Disease Week will take place virtually October 21-25. Among the data to watch are the Phase II results with a 20-valent pneumococcal vaccine, Pfizer’s 20vPnC (PF-06482077).

Medical devices: FDA’s Patient Engagement Advisory Committee will meet virtually October 22 to discuss artificial intelligence and machine learning (AI/ML) in medical devices. The panel will discuss the composition of the datasets on which the software “learns,” components of the device information shared with patients, and factors that impact patient trust in the technology. The panel also will address the importance of including various demographic groups in AI/ML algorithm development, the impact of the user interface, and transparency.

Nephrology: The American Society of Nephrology (ASN): Kidney Week 2020 Reimagined will take place virtually October 19-25. Among the data to watch are:

  • The results of the Phase III ILLUMINATE-B trial of an RNAi therapeutic (Alnylam Pharmaceuticals’ lumasiran) in pediatric primary hyperoxaluria type 1.
  • The results of the Phase II DUET trial of Retrophin’s sparsentan for focal segmental glomerulosclerosis.

Neurology: The Child Neurology Society joint virtual meeting with the International Child Neurology Congress will take place October 12-23, but the key dates are 19-23. Among the data to watch is additional data from a Phase I/II trial of a CLN6 gene therapy for Batten disease (Amicus Therapeutics’ AT-GTX-501).


  • The FDA is expected to make a decision by October 24 on a treatment for chemotherapy-induced neutropenia – Spectrum Pharmaceuticals’ Rolontis (eflapegrastim).
  • The Prostate Cancer Foundation Scientific Retreat will take place virtually October 20-23. The focus is basic, translational, and clinical science, but there will also be sessions on genomics, diversity, and more. Among the late-breaking prostate cancer data will be the results of Phase I trials of a PSCA-targeted CAR T therapy (Mustang Bio’s MB-105) and two bispecific T-cell engager antibodies (Amgen’s AMG-160 and AMG-509).
  • The Innovation and Biomarkers in Cancer Drug Development (IBCD) meeting will take place virtually October 23. Topics will include drug and biomarker development, comparative effectiveness research, the translation of trial data into daily practice, and the emergence of new regulatory routes to approve new cancer drugs based on biomarkers.
  • The International Symposium on Minimal Residual Cancer (ISMRC): The Liquid Biopsy Conference will take place virtually October 24-25. Topics will include circulating tumor cells, circulating nucleic acids and exosomes, the biology of metastasis, and more. Watch for: Updated data from the Phase I/II KRYSTAL trial on Mirati Therapeutics’ MRTX-849, a KRAS inhibitor, as monotherapy for non-small cell lung cancer (NSCLC) and colorectal cancer; Phase I data on Syros Pharmaceuticals’ SY-5609, a CDK7 inhibitor, in solid tumors.


  • The American College of Chest Physicians (CHEST) will take place virtually October 18-21. Topics will include telemedicine, pulmonary sarcoidosis, new developments in the management of mycobacterial and bacterial chest infections, and the respiratory effects of Covid-19. Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID), will give the keynote address.
  • The North American Cystic Fibrosis Conference (NACFC) will take place virtually October 21-23.


  • The FDA and the Drug Information Agency (DIA) are holding a two-day virtual conference on October 19-20 on complex generic drug-device combination products. This will be an update on ongoing research to address the challenges posed with these products.
  • On October 19 the FDA is holding the first webcast of a series of Digital Health Center of Excellence Listening Sessions. It is an opportunity for people to learn more about this new FDA center and for the FDA to get feedback on ways to advance the potential of digital health.
  • The FDA’s Oncology Center of Excellence will host a Conversation on Cancer webcast on October 22 to discuss participation in clinical trials in breast cancer by Native Americans.
  • The FDA, in collaboration with the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI), is holding a two-day virtual public workshop on October 22-23 on pediatric dose selection, looking for new ways to address issues with dose selection in pediatric drug development.

Reproductive medicine: The American Society for Reproductive Medicine (ASRM) virtual meeting will continue through October 21.

Lynne Peterson, Contributing Writer, Senior Writer for Trends-in-Medicine

Cat ID: 190

Topic ID: 79,190,730,316,935,190,31,846,926,541,130,192,418,725,195,225,925